Zobrazeno 1 - 10
of 24
pro vyhledávání: '"N. Steen Krogh"'
Autor:
H. Leffers, D. Westergaard, S. Saevarsdottir, I. Jonsdottir, O. B. Pedersen, A. Troldborg, A. Voss, S. Kristensen, J. Lindhardsen, P. Kumar, A. Linauskas, L. Juul, N. Steen Krogh, B. Deleuran, L. Dreyer, M. Schwinn, L. W. Thørner, L. Hindhede, C. Erikstrup, H. Ullum, S. Brunak, K. Stefansson, K. Banasik, S. Jacobsen
Publikováno v:
Annals of the Rheumatic Diseases. 81:1138-1139
BackgroundSystemic lupus erythematosus (SLE) has been associated with more than 100 genetic loci. This parallels positively to the clinical diversity that is reflected by the classification of SLE.ObjectivesWe aimed to investigate associations betwee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe581337b83dd72d5569b19c07d80961
https://doi.org/10.1136/annrheumdis-2022-eular.2481
https://doi.org/10.1136/annrheumdis-2022-eular.2481
Autor:
H. Nabi, M. L. Hetland, A. G. Loft, O. Hendricks, D. Jensen, J. K. Pedersen, S. A. Just, K. Danebod, H. L. Munk, S. Kristensen, N. Manilo, A. Colic, A. Linauskas, P. H. Thygesen, L. B. Christensen, M. Høgberget Kalisz, N. Lomborg, J. Grydehøj, J. Raun, R. Ahmed, F. Mehnert, N. Steen Krogh, B. Glintborg
Publikováno v:
Annals of the Rheumatic Diseases. 81:45-46
BackgroundIn routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from originator infliximab to a corresponding biosimilar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0026585463d665fe41da2631ed86c161
https://doi.org/10.1136/annrheumdis-2022-eular.2306
https://doi.org/10.1136/annrheumdis-2022-eular.2306
Autor:
M. Wetterslev, S. Georgiadis, S. N. Christiansen, S. J. Pedersen, I. J. Sørensen, M. L. Hetland, A. Duer, M. Boesen, K. K. Gosvig, J. Møllenbach Møller, M. Bakkegaard, C. H. Brahe, N. Steen Krogh, B. Jensen, O. Madsen, J. Christensen, A. Hansen, J. Noerregaard, H. Røgind, M. Østergaard
Publikováno v:
Annals of the Rheumatic Diseases. 81:396-397
BackgroundPatients with axial spondyloarthritis (axSpA) in clinical remission tapered Tumor Necrosis Factor inhibitor (TNFi) therapy according to a clinical guideline and had 2 years´ follow-up [1].ObjectivesWe aimed to investigate flare frequency,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb347e0b4386a8de738f4c3fb49c63d6
https://doi.org/10.1136/annrheumdis-2022-eular.654
https://doi.org/10.1136/annrheumdis-2022-eular.654
Autor:
B. Glintborg, D. V. Jensen, L. Terslev, O. Hendricks, M. Østergaard, S. H. Rasmussen, M. Pfeiffer-Jensen, T. Adelsten, A. Colic, K. Danebod, M. Kildemand, A. G. Loft, H. L. Munk, J. K. Pedersen, R. Østgård, C. M. Sørensen, N. Steen Krogh, J. Nørgaard Agerbo, C. Ziegler, M. L. Hetland
Publikováno v:
Annals of the Rheumatic Diseases. 81:440.2-441
BackgroundDigital solutions for online monitoring of chronic diseases are increasingly implemented in health care, but not all patients might have access, skills, or interest in using them. Fueled by the COVID-19 pandemic and the urgent need for remo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b40246d704f801e94e421e3cbc08d8e
https://doi.org/10.1136/annrheumdis-2022-eular.990
https://doi.org/10.1136/annrheumdis-2022-eular.990
Autor:
B. Glintborg, D. V. Jensen, L. Terslev, O. Hendricks, M. Østergaard, S. H. Rasmussen, M. Pfeiffer-Jensen, T. Adelsten, A. Colic, K. Danebod, M. Kildemand, A. G. Loft, H. L. Munk, J. K. Pedersen, R. Østgård, C. M. Sørensen, N. Steen Krogh, J. Nørgaard Agerbo, C. Ziegler, M. L. Hetland
Publikováno v:
Annals of the Rheumatic Diseases. 81:944.2-945
BackgroundPatients with inflammatory rheumatic diseases (IRD) have used self-isolation and social distancing during the pandemic to avoid SARS-CoV-19 infection (reference). In countries with unlimited and free access to SARS-CoV-19 testing, anxiety o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8899717b61451a2f65ffa60b91274e34
https://doi.org/10.1136/annrheumdis-2022-eular.2234
https://doi.org/10.1136/annrheumdis-2022-eular.2234
Autor:
C. Graversgaard, K. Schreiber, R. Petersen, H. Jakobsen, A. B. Bojesen, N. Steen Krogh, B. Glintborg, M. L. Hetland, O. Hendricks
Publikováno v:
Annals of the Rheumatic Diseases. 81:332.1-333
BackgroundDuring the COVID-19 pandemic, it remains a major concern whether patients with rheumatic musculoskeletal disease treated with conventional (cs) or biologic (b) disease modifying drugs (DMARDs) exhibit an adequate immune response to the curr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4544ac5aaca6972a81389a623001f20e
https://doi.org/10.1136/annrheumdis-2022-eular.3106
https://doi.org/10.1136/annrheumdis-2022-eular.3106
Autor:
Sella Aarrestad Provan, Lotta Ljung, Johan Askling, N. Steen Krogh, K. Lederballe Gron, Brigitte Michelsen, Nina Trokovic, Heikki Relas, B. Glintborg, M.L. Hetland, Carl Turesson, Bénédicte Delcoigne
Publikováno v:
Annals of the Rheumatic Diseases. 80:63-64
Background:Rheumatoid Arthritis (RA) is associated with increased cardiovascular co-morbidity including acute coronary syndrome (ACS), partly due to effects of systemic inflammation. Disease-modifying anti-rheumatic drugs (DMARDs) may reduce RA disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0f73b9cd08547a130f6ae32c33da7d8
https://doi.org/10.1136/annrheumdis-2021-eular.2626
https://doi.org/10.1136/annrheumdis-2021-eular.2626
Autor:
Kamilla Danebod, Niels Lomborg, T. Thorgrimsen, Oliver Hendricks, Marlene Andersen, Hanne Merete Lindegaard, R. Ahmed, G. Kollerup, D. V. Jensen, N. Steen Krogh, Jolanta Grydehøj, M. Kalisz, B. Glintborg, I. Ruge, K. Mortensen, Anne Gitte Loft, Line Uhrenholt, Johnny Lillelund Raun, M.L. Hetland, Ada Colic
Publikováno v:
Annals of the Rheumatic Diseases. 79:1001-1002
Background:Smoking is a known risk factor for rheumatoid arthritis (RA). It is largely unknown whether smoking has any impact on disease activity and treatment outcomes (e.g. achieving remission on methotrexate and time to first biological disease mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::521e920573b0d2ddb4abaa9af50476d9
https://doi.org/10.1136/annrheumdis-2020-eular.2344
https://doi.org/10.1136/annrheumdis-2020-eular.2344
Autor:
Dan Nordström, Bjorn Gudbjornsson, Michael John Nissen, D. Di Giuseppe, Brigitte Michelsen, Manuel Pombo-Suarez, G. Yıldırım Çetin, Pedro Avila-Ribeiro, Karen Minde Fagerli, Catalin Codreanu, Heřman Mann, N. Steen Krogh, Matija Tomšič, Anne Gitte Loft, B. Glintborg, Adrian Ciurea, Heikki Relas, Nurullah Akkoc, L. T. H. Jacobsson, Ulf Lindström, M.L. Hetland, Lucie Nekvindová, I E van der Horst-Bruinsma, Ruxandra Ionescu, Johan Askling, Florenzo Iannone, Arni Jon Geirsson, Carlos Sánchez-Piedra, Gary J. Macfarlane, M. J. Santos, Ziga Rotar, B. Moeller, Bénédicte Delcoigne
Publikováno v:
Annals of the Rheumatic Diseases. 79:71-72
Background:Axial spondylarthritis (axSpA) patients treated with a tumour necrosis factor inhibitor (TNFi) may receive a concomitant conventional synthetic disease-modifying anti-rheumatic drug (csDMARD), although the value of combination therapy rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::625adcbef3ecc52f63635a0051539dbc
https://doi.org/10.1136/annrheumdis-2020-eular.1804
https://doi.org/10.1136/annrheumdis-2020-eular.1804
Autor:
Mikkel Kramme Abildtoft, Peter C. Taylor, Lene Dreyer, A. S. Mortensen, N. Steen Krogh, Line Uhrenholt, Robin Christensen, Salome Kristensen, Ellen Margrethe Hauge
Publikováno v:
Annals of the Rheumatic Diseases. 79:1919-1920
Background:Patient-reported outcome measures (PROMs) are essential to understand the patient’s perception of arthritis activity. In Demark, PROMs are registered on a touchscreen in the outpatient clinic. However, some patients find it inconvenient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4039b63b7da01bae7b3b0d546fb99f8
https://doi.org/10.1136/annrheumdis-2020-eular.523
https://doi.org/10.1136/annrheumdis-2020-eular.523